MacroGenics | MGNX - Cost Of Sales


MacroGenics reported $9.53M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.29B 73M Jun/2026
Amgen USD 1.87B 271M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
Genmab DKK 84M 19M Jun/2026
Geron USD 1.69M 386K Mar/2026
Gilead Sciences USD 1000M 445M Jun/2026
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merck USD 3.14B 200M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 576.5M 92.9M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025